COMPOUND MEDICATIONS PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the provider may complete this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit https://www.bcbstx.com/provider/medicaid/pharmacy/star-kids-prior-auth PATIENT AND INSURANCE INFORMATION Today's Date: Patient Name (First): DOB (mm/dd/yyyy): Patient Address: City, State, Zip: Patient Telephone: BCBSTX ID Number: Group Number: PRESCRIBER/CLINIC INFORMATION Prescriber Name: Prescriber NPI#: Specialty: Contact Name: Clinic Name: Clinic Address: City, State, Zip: Phone #: Secure Fax # PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST Patient's Diagnosis - ICD code plus description: Medication Requested: Strength: Quantity per Month: Dosing Schedule: For ALL Compound Requests: If no, when was treatment with the requested medication started?____ 2. Please list all ingredients (attach additional pages if needed): Product (include strength if applicable) Quantity (include unit of measure) 3. Please list all reasons for selecting the requested compound, quantity and dosing schedule over alternatives (e.g., contraindications or allergies to alternatives/preservatives/dyes/fillers, unable to swallow capsules/tablets). 4. Does the patient have a G- or J-tube? Please continue to page 2.

6182 TXSK COMP 0422 Page **1** of **2**

Patient Name (First):		Last:		M:	DOB (mm/dd/yy):	
For compounded vancomycin suspension:						
5. Does the patient have Staphylococcal enterocolitis infection?						
6.	Does the patient have Clostridium difficile-associated diarrhea caused by Staphylococcal enterocolitis?					
0.						
	If yes, has the patient tried metronidazole for this infection?					
For compounded tobramycin, gentamicin, or colistin inhalation solution:						
7.	Is the requested agent prescribed for cystic fibrosis or lung infection caused by Pseudomonas aeruginosa? Yes					☐ No
8.	Is the patient pregnant?				Yes	☐ No
9.	Is the requested agent being used for	or inhalation only?			Yes	☐ No
10. Is the patient currently using other inhaled antibiotics/anti-infective agents, including alternating treatment						
schedules?						☐ No
If yes , will the other agent(s) be discontinued prior to starting this requested compound? ☐ Yes					☐ No	
11. For tobramycin inhalation, is the patient colonized with Burkholderia cepacia?					☐ No	
12.	12. Does the patient have an FEV1 < 90% of predicted?					☐ No
For compounded hydroxyprogesterone injection:						
13. Is the patient a pregnant female?					□No	
14. How many weeks gestation is the patient? weeks and days						
						☐ No
16. Has the patient had at least one spontaneous singleton preterm pregnancy in the past (defined as before 37						
weeks' gestation?						∐ No
17. Currently, does the patient have any of the following? <i>Check all apply.</i> ☐ An interval of less than 6 months between pregnancies						
☐ Conception through in vitro fertilization						
☐ Problems with uterus, cervix, or placenta						
☐ Smoke cigarettes, drink alcohol, or use illicit drugs						
For compounded bulk powder progesterone:						
17.	Is the requested agent being used to	promote fertility?			Yes	☐ No
Prescriber or Authorized Signature: Date: Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a						
treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information						
regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.						
Note: Payment is subject to member eligibility. Authorization does not guarantee payment.						
Please fax or mail this form to: Prime Therapeutics LLC, Clinical Review Department			the use of the individual entity t			,
2900 Ames Crossing Road		information that is privileged or confidential. If the reader of this message				
Eagan, Minnesota 55121		is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly				
TOLL FREE			prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return the			
Fax: 877.243.6930 Phone: 855.457.1200			original message to Prime The			
			cooperation.		-	

6182 TXSK COMP 0422 Page 2 of 2